Akademik Veri Yönetim Sistemi
Radionuclide Therapy, Recep Bekiş,Berna Polack,Murat Fani Bozkurt, Editör, Springer, London/Berlin , London, ss.301-310, 2022
Prostate cancer is the most common cancer in the males. It ranks second in cancer-related deaths in the males [1]. The most common symptoms are frequent urination, difficulty in urinating, dysuria, nocturia, and hematuria even though most patients with early prostate cancer are asymptomatic. Pain in the pelvic region and bone pain may also occur at later stages. There are no symptoms specific to prostate cancer. However, it is necessary to suspect in patients who describe these symptoms. Digital rectal examination (DRE) and prostate-specific antigen (PSA) measurement are the two most important parameters in the diagnosis of prostate cancer. Prostate biopsy is required when these two parameters are abnormal. Prostate biopsy is performed with transrectal ultrasound (TRUS). Studies have been conducted to increase diagnostic accuracy with prostate biopsy accompanied by multiparametric MRI (mpMRI) [2]. It has been adopted by international guidelines that prostate biopsy should be taken from at least 12 quadrants [3]. Sometimes biopsy may be benign despite all efforts. Biopsy should be repeated if DRE suggests prostate tumor and PSA continues to increase in such cases.